Winning the AI-First Patient & HCP Journey in Pharma Brands
Winning the AI-First Patient & HCP Journey in Pharma Brands
Patients and HCPs start their journey in AI search. Learn how pharma brands can build AI visibility, stay compliant, and win the AI-first healthcare journey.
Haritha Kadapa
A Q&A on how pharma brands can show up and stay visible where healthcare decisions now begin. This builds on broader GEO principles for pharma AI visibility, where structural content design and external authority determine whether brands appear in AI responses.
Q: What does the "AI-first patient and HCP (Healthcare Professional) journey" actually mean in pharma?
It means the first touchpoint in a healthcare decision is no longer a search results page; it's an AI response.
A patient researching a new diagnosis types their question into AI platforms like ChatGPT or Perplexity. A HCP comparing treatment options gets a synthesized response from Google AI Overviews before they ever visit a brand website. A hospital procurement lead asks an AI assistant to shortlist formulary options. In each case, one answer appears. It draws from a small set of trusted sources, and most pharma brands aren't among them.
Q: If pharma brands aren't showing up in AI responses, who is?
Aggregators.
Assume a patient is seeking treatment options for a chronic condition, the response typically comes from WebMD, Healthline, Verywell Health, or similar third-party health content platforms.
When an HCP asks about comparative efficacy, the answer draws on PubMed abstracts, clinical guideline bodies, and government health databases.
In both cases, the Pharma brand with the most complete, accurate, and approved information about its own therapy is absent.
This is a displacement problem, distinct from simply not ranking well. Aggregators usually publish content at high volume. They are consistently cited across the web, and have content formatted in exactly the question-and-answer structures that AI platforms extract most readily. A pharma brand competing against that on owned channels alone is not a fair fight.
Q: How would a pharma marketing team even know if their AI visibility is a problem?
Right now, most wouldn't.
AI visibility in Pharma brands is currently a blind spot. Standard marketing dashboards track organic search rankings, paid media performance, website traffic, and HCP portal engagement.
Pharma brands still rely on traditional channel metrics and measure the same channels they have always measured. Meanwhile, AI search is shaping decisions, and many brands do not realize how much visibility they are already losing there.
The starting point is straightforward: run the queries your patients and HCPs are already running. Open ChatGPT, Perplexity, and Google AI Overviews. Type in the real questions by condition, by therapy class, or by drug name. Look at what comes back. Look at what doesn't. That query audit, done systematically and repeated over time, is the baseline measurement that should sit alongside every other channel metric a pharma marketing team track.
|
Q: What does it mean for AI to misrepresent a therapy?
Misrepresentation in AI responses takes a few forms.
The most common is omission: a drug exists and has strong clinical data but doesn't appear in the AI response because the LLM doesn't have sufficient grounding in it.
The second form is inaccuracy: the AI response includes the brand but associates it with incorrect dosing, outdated safety information, or a mischaracterized indication.
The third is framing: the therapy is mentioned, but in a context that positions it unfavorably relative to a competitor, often because the sources the LLM drew on weren't neutral.
All three occur, but none trigger an alert in a standard pharma monitoring setup. Research found that leading AI models can reproduce false medical claims when they appear in familiar clinical language, and that existing safeguards do not reliably catch them.
For regulated industries, this is a materially different kind of risk than a negative press article or a bad search result. Typically, you can address a bad search result by implementing an SEO strategy and creating owned content. An AI response, on the other hand, that consistently mischaracterizes a therapy's safety profile has no clear correction pathway. The AI's outputs are probabilistic, variable, and shaped by the full distribution of content it has been trained on and that it retrieves.
Q: Does AI visibility matter more at certain points in a drug's lifecycle?
Yes. The launch window is where the stakes are highest, and the vulnerability is greatest.
At launch, the LLM has little or no training data about the new therapy, no established citation pattern, and no external references to draw on. HCPs searching for new treatment options in that category will receive responses that don't include it. This happens not because it has been evaluated and dismissed, but because it doesn't yet exist in the LLM's frame of reference.
Research on LLM knowledge cutoffs shows that a model's effective knowledge of recent content frequently lags behind its reported training date. It means the gap between a drug's approval and its presence in AI responses can be longer than most pharma teams anticipate.
Q: What does a GEO strategy look like for a pharma brand operating under regulatory constraints?
It looks less different from compliant content practice than most teams assume.
The core regulatory requirement that every clinical claim be accurate, approved, and substantiated is also exactly what AI platforms need to reliably surface content. Structured prescribing information, clearly stated indications, evidence-backed efficacy and safety data, consistent drug nomenclature: these are not in tension with GEO. They are GEO, formatted correctly.
Where pharma brands lose ground is not in what they say, but in how they organize it. Approved content buried in dense PDFs, indication language that varies slightly across platforms, dosing information three clicks deep in a microsite: none of this violates regulatory standards, but all of it reduces how reliably AI platforms can read and retrieve it. A GEO strategy operates under regulatory constraints as a structural exercise: it involves clearly presenting what has already received approval. The regulatory review process remains unchanged; only the presentation of the approved output has altered.
Q: How is AI visibility for pharma different from traditional earned media or PR?
It looks less different from compliant content practice than most teams assume.
In PR, there is always a correction pathway. A negative article has a journalist behind it, an editor above them, and a publication with a reputation to protect. A pharma brand can respond, provide accurate clinical data, and request a correction. The process is slow, but it exists.
With AI, it doesn't. If a model consistently omits a therapy from treatment comparisons, mischaracterizes its indication, or surfaces outdated safety data, there is no editorial contact, no correction request, and no appeals process. The model generates the output probabilistically, influenced by everything it has been trained on. A brand cannot intervene in the way it would with a publisher.
The second difference is trust. A reader encountering a press article knows it came from somewhere, a named journalist, a named publication, and can factor that in. An AI response arrives as a direct answer with no visible source. Most HCPs and patients take it at face value. That makes upstream accuracy what your clinical content says, where it lives, and how consistently it is cited, the only real lever a pharma brand has.
Q: What does it actually mean to "own" a therapy area in AI search, and is that a realistic goal for pharma?
It's realistic, but it requires a more specific definition than the phrase usually gets.
Owning a therapy area in AI search doesn't mean controlling the LLM's outputs or guaranteeing that your brand appears in every response. AI platforms are not advertising channels and don't work on a pay-to-play basis. What it does mean is consistently being the primary cited source for a defined set of questions, the queries that matter most to your HCP and patients across the AI platforms.
That kind of presence is built, not bought. It comes from having the most structured, specific, and externally corroborated clinical content in a given therapy area. A brand that has published clearly structured prescribing information, contributed to peer-reviewed literature, maintained an accurate presence in clinical databases, and built a track record of being cited by authoritative medical sources is the brand that AI platforms will consistently surface.
|
Q: What should a pharma brand do in the first 90 days to improve its AI visibility?
The first 90 days should focus on diagnosis and structural correction, not content expansion.
Brands should begin by auditing how their therapy areas appear across AI platforms using real HCP and patient queries. This establishes a baseline of where the brand is visible, missing, or misrepresented.
Next, existing clinical and regulatory content should be restructured into answer-first formats with clear headings, defined sections, and extractable clinical statements. In parallel, teams should map external citation gaps by reviewing presence across clinical trial registries, peer-reviewed publications, and medical databases.
The outcome of this phase is not full optimization, but a clear visibility map and a prioritized set of structural fixes that directly impact AI retrieval.
Free AI Visibility Audit
Limited Availability.
VISIBILITY & CONTENT STRATEGY
